DOI: https://doi.org/10.2298/SARH260603070V
UDC: 616.8-009.7:577.112; 618.19-006-089.168

ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД

Preoperative C-reactive protein predicts next-day pain after breast tumor surgery

Bojana Vidović[1], Ana Sekulić[1,2], Sanja Vignjević Petrinović[3], Nataša Čolaković[1,2], Simona Petričević[1,2], Milan Gojgić[1], Barbara Loboda[1], Darko Zdravković[1,2]

[1]Bežanijska Kosa University Hospital Medical Center, Belgrade, Serbia;
[2]University of Belgrade, Faculty of Medicine, Belgrade, Serbia;
[3]University of Belgrade, National Institute of Republic of Serbia, Institute for Medical Research, Belgrade, Serbia

SUMMARY

Introduction/Objective Subclinical inflammation is increasingly recognized as a driver of postoperative pain, yet its role in breast tumor surgery is not fully defined.

The objective was to determine whether preoperative C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) predicts acute postoperative pain (APSP); to examine how surgical extent influences the perioperative inflammatory response; and to explore the relation between intraoperative fentanyl and pain intensity.

Methods In a prospective single-center cohort, 101 adults scheduled for breast surgery were stratified into four groups: mastectomy (M, n = 25), tumorectomy (T, n = 28), tumorectomy plus axillary dissection (T + A, n = 20), and benign excision (C, n = 28). Venous blood was drawn on admission (T0) and at 24 h (T24) for CRP and ESR. Pain was assessed with an 11-point Numerical Rating Scale 30 min after recovery and at 24 h; the highest 24-h score (max-APSP) was the primary pain outcome.

Results Preoperative CRP correlated with max-APSP ($p = 0.043$), whereas ESR did not ($p = 0.11$). Baseline CRP and ESR, and their 24-hour increments, rose stepwise with surgical magnitude, peaking after mastectomy (baseline CRP 7.1 ± 1.9 mg/L; T24 27.5 ± 3.6 mg/L; both $p < 0.01$ *vs.* other groups). Intraoperative fentanyl correlated with CRP at 24 hours ($r = 0.33$, $p = 0.001$) and with max-APSP ($r = 0.28$, $p = 0.005$). Despite these biological gradients, mean max-APSP remained mild to moderate across groups.

Conclusion Presurgical systemic inflammation, reflected by CRP, independently predicts early pain after breast tumor surgery. Surgical magnitude amplifies inflammatory markers, and greater fentanyl exposure parallels both inflammation and pain. Routine perioperative CRP may help identify high-risk patients for targeted anti-inflammatory and opioid-sparing analgesic strategies to reduce acute pain and potentially mitigate chronic pain development.

Keywords: acute postoperative pain; breast tumor surgery; C-reactive protein; erythrocyte sedimentation rate

INTRODUCTION

Breast cancer surgery is among the most frequently performed oncological procedures worldwide. Each year, more than two million women are diagnosed with breast cancer, with surgery remaining a core treatment modality [1, 2]. Despite advances in anesthetic and analgesic techniques, acute postoperative pain (APSP) remains common; observational data suggest that up to 60% of patients report severe pain within the first 24 hours, and inadequate early control is associated with a higher risk of persistent postsurgical pain (PPSP) [3, 4]. Unrelieved APSP impairs shoulder mobility, delays hospital discharge, and independently predicts poorer health-related quality of life, reinforcing the need for early risk stratification and procedure-specific, opioid-sparing multimodal pathways [4].

A growing body of translational research links perioperative systemic inflammation to nociceptive sensitization. Recent neurobiological evidence indicates that perioperative tissue injury can activate immune–neuronal and glial pathways, promoting proinflammatory mediator release, peripheral sensitization and central sensitization [5]. In parallel, experimental and clinical studies have associated circulating inflammatory markers, particularly C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR), with heightened pain sensitivity, although the strength and timescale of these associations vary across settings [6, 7]. CRP, an acute-phase reactant predominantly regulated by interleukin-6, is a pragmatic index of short-term inflammatory flux, whereas ESR, though widely available, is less specific and may reflect chronic processes [8]. In mastectomy cohorts, higher CRP on postoperative day 1, alongside acute pain severity, has been associated with later PPSP/chronic postsurgical pain, supporting the premise that early inflammatory load shapes pain trajectories [9, 10].

Breast surgery provides a clinically relevant model to explore these relationships. Thus, the procedures share local tissue characteristics yet differ markedly in surgical scope – from

Received • Примљено: June 3, 2026
Revised • Ревизија: July 17, 2026
Accepted • Прихваћено: August 24, 2026
Online first: September 7, 2026

Correspondence to:
Barbara LOBODA
Marije Bursać 6/8
11080 Belgrade, Serbia
barbara.loboda@hotmail.com

breast-conserving tumorectomy to mastectomy with axillary clearance, creating a natural gradient of tissue trauma and systemic inflammatory response [11]. Contemporary evidence supports regional analgesia as an important component of opioid-sparing postoperative pain management after breast cancer surgery [12]. Existing literature has extensively examined CRP in breast cancer, including its prognostic value across patient subgroups [13]. Moreover, prior reports seldom adjust for intraoperative opioid dose, although experimental and translational evidence suggests that opioid exposure may paradoxically amplify postoperative nociception through neuroinflammatory mechanisms consistent with opioid-induced hyperalgesia [14].

To address these gaps, we conducted a prospective, single-center observational study of patients undergoing breast tumor surgery. We tested three prespecified hypotheses: (i) higher preoperative CRP and ESR are associated with greater APSP intensity at 24 h; (ii) postoperative inflammatory marker levels rise in proportion to surgical extent; and (iii) intraoperative fentanyl dose correlates positively with APSP intensity at 24 h. By clarifying how routine inflammatory biomarkers relate to early pain outcomes across different surgical magnitudes, our findings aim to inform risk-stratified analgesic planning and to stimulate future interventional trials that target perioperative inflammation in breast cancer patients.

METHODS

Study design and participants

A prospective, single-center observational study was conducted at the Department of Oncological Surgery, Bežanijska Kosa University Hospital Medical Center, Belgrade, Serbia, between August 1 and November 30, 2022. The study was approved by the Institutional Ethics Committee of the Bežanijska Kosa Clinical Hospital Center (protocol No. 4831/1, 22.07.2022). All participants provided written informed consent. The investigation complied with the Declaration of Helsinki and followed General Data Protection Regulation-compliant data-protection procedures.

Consecutive adult patients (≥ 18 years) scheduled for elective breast tumor surgery were screened. Inclusion criteria were: histologically confirmed breast tumor (benign or malignant), physical status I–III, planned postoperative ward admission, and written informed consent. Exclusion criteria comprised incomplete medical records, pre-existing breast pain on the day of surgery, withdrawal of consent at any time, locally advanced or metastatic disease (stage IV), allergy to anesthetic agents, or intra-/early postoperative complications requiring protocol deviation. After screening 142 patients, 101 met all criteria and were enrolled. According to surgical extent and final histology, they were stratified into four predefined groups: 1) Mastectomy (M) – malignant, entire breast removed (n = 25); 2) Tumorectomy (T) – malignant, tumor excision only (n = 28); 3) Tumorectomy + axillary dissection (T + A) – malignant, tumor excision with axillary clearance (n = 20); 4) Benign excision (C) – benign lesion removed (n = 28).

Methods

General anesthesia was standardized in all study groups. Anesthesia was induced with propofol (1.5 mg/kg intravenously) and rocuronium bromide (0.9–1.2 mg/kg intravenously) to facilitate endotracheal intubation. Anesthesia was maintained with sevoflurane in an oxygen/air mixture, with the end-tidal concentration adjusted according to routine clinical practice to maintain an adequate depth of anaesthesia. Intraoperative analgesia consisted of fentanyl administered intravenously and titrated according to the patient's clinical response and the extent of the surgical procedure. Additional fentanyl was titrated at the anesthetist's discretion and the total intraoperative dose was recorded (50 μg/mL solution).

Venous blood was drawn on admission (T_0) and at 24 h post-surgery (T_{24}). ESR (mm/h) and CRP (mg/L) were analyzed in the hospital laboratory using standardized turbidimetric assays.

Acute postoperative pain in the surgical breast was measured with an 11-point Numerical Rating Scale (NRS; 0 = no pain, 10 = worst imaginable) – a tool validated for postoperative settings. Scores were obtained at T_0, 30 min after arrival in the recovery room ($T_{0.5}$), and at T_{24}. For analysis, the highest score within the first 24 h was designated the maximal acute postoperative pain (max-APSP). Between the scheduled pain assessments (30 minutes and 24 hours after surgery), postoperative analgesia consisted of non-steroidal anti-inflammatory drugs, administered according to the institutional postoperative pain protocol and routine clinical assessment by the nursing staff. The same postoperative analgesic strategy was applied to all study groups.

Primary outcome: association between preoperative CRP/ESR and max-APSP. Secondary outcomes: (i) relationship between surgical extent and postoperative CRP/ESR; (ii) correlation between intraoperative fentanyl dose and maximal acute postoperative pain.

Statistical analysis

Continuous variables are reported as means ± standard errors of the mean (SEM) with ranges, and categorical variables as counts (percentages). Normality was assessed with the Shapiro–Wilk test and inspection of quantile–quantile plots; homogeneity of variances with Levene's test. Between-group comparisons used one-way analysis of variance (ANOVA) when assumptions were met; post hoc tests were selected a priori according to variance diagnostics: least significant difference (LSD) or Bonferroni when variances were homogeneous, and Games–Howell when they were not. Associations between continuous measures were examined using Pearson's correlation coefficient (r) after checking linearity and distributional assumptions. To assess whether preoperative CRP was independently

associated with maximum 24-hour APSP, a multivariable linear regression analysis within the general linear model framework was performed. Surgical group was entered as a fixed categorical factor, whereas preoperative CRP, preoperative ESR, intraoperative fentanyl dose, age and body mass index (BMI) were entered as covariates. All tests were two-sided with $\alpha = 0.05$. Analyses were performed using IBM SPSS Statistics, Version 25.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Participants' baseline characteristics

The patients who met all eligibility criteria were enrolled (N = 101). Almost the entire cohort was female (100/101, 99%). Mean age was 56.4 ± 1.7 years (range 19–88) and differed across surgical-extent strata: benign excision (C) patients were significantly younger than all malignancy groups (ANOVA F = 25.622, p < 0.001). The four predefined groups comprised 25 mastectomies (M) – mean age 61.96 ± 2.56 years (32–81); 28 tumorectomies (T) 65.93 ± 2.48 years (41–88); 20 tumorectomies with axillary dissection (T + A) 61.76 ± 2.43 years (38–76); and 28 benign excisions (C) 38.07 ± 2.79 years (19–71) (Figure 1A).

The mean tumor size across all patients was 23.45 ± 1.35 mm (range 8–98). By group, mean sizes were as follows: C, 21.42 ± 1.69 mm (10–47); M, 28.58 ± 3.82 mm (10–98); T, 21.11 ± 1.58 mm (8–40); and T + A, 23.2 ± 3.56 mm (10–80). There was no statistically significant difference in tumor size between the groups (ANOVA: F = 1.684; p > 0.05) (Figure 1B).

The mean BMI for the cohort was 25.84 ± 0.46 kg/m² (range 15.92–38.54). By group, mean BMI values were as follows: C, 23.31 ± 0.88 kg/m² (15.92–34.89); M, 26.52 ± 0.87 kg/m² (20.2–36.25); T, 27.56 ± 0.91 kg/m² (18.29–38.54); and T + A, 26.11 ± 0.82 kg/m² (17.72–32.83). Patients with malignant breast tumors who underwent tumor excision (T) had a significantly higher BMI than those who underwent excision of a benign lesion (C) (ANOVA: F = 4.634; p < 0.05) (Figure 1C).




Figure 1. Baseline characteristics by surgical group; (A) age (years); one-way ANOVA with Bonferroni post hoc testing, p < 0.010; (B) tumor size (mm); one-way ANOVA, F = 1.684, p > 0.050; (C) body mass index (kg/m²); one-way ANOVA with Bonferroni post hoc testing, p < 0.050; data are mean ± SEM;
C – benign lesion excision; T – malignant tumorectomy; T + A – malignant tumorectomy with axillary dissection; M – mastectomy; significance: p < 0.050

Primary outcome – association between preoperative inflammation and 24-hour pain

In analyses of patients undergoing surgical excision of a breast tumor, a statistically significant correlation was observed between admission CRP and the maximum intensity of acute postoperative pain at 24 hours (Pearson's r = 0.246; 95% confidence interval (CI) 0.053–0.421; p < 0.05; Table 1). Admission CRP also correlated significantly with CRP at 24 hours (r = 0.574; 95% CI 0.426–0.692; p < 0.001), with the ESR at admission (r = 0.553; 95% CI 0.401–0.675; p < 0.001) and at 24 hours (r = 0.539; 95% CI 0.384–0.664; p < 0.001), as well as with the intraoperative fentanyl dose (r = 0.232; 95% CI 0.038–0.409; p < 0.05).

In addition to its positive correlation with admission CRP, the intraoperative fentanyl dose correlated significantly with CRP at 24 hours (r = 0.325; 95% CI 0.138–0.489; p = 0.001), with ESR at admission (r = 0.256; 95% CI 0.064–0.430; p = 0.01), and with the maximum intensity of acute postoperative pain at 24 hours (r = 0.279; 95% CI 0.088–0.450; p < 0.01) (Table 1).

To address potential confounding, a multivariable linear regression analysis within the general linear model framework was performed with maximum 24-hour APSP as the dependent variable. Surgical group was entered as a fixed categorical factor, while preoperative CRP, preoperative ESR, intraoperative fentanyl dose, age and BMI were entered as covariates. The overall model was statistically significant (F = 2.860, p = 0.007; $R^2 = 0.199$; adjusted $R^2 = 0.130$). Preoperative CRP remained independently associated with maximum 24-hour APSP after adjustment for surgical group, preoperative ESR, intraoperative

Table 1. Correlations of CRP at admission and intraoperative fentanyl dose with inflammatory markers and pain outcomes

Variable	Admission CRP r (95% CI)	Admission CRP (p)	Intraoperative fentanyl r (95% CI)	Intraoperative fentanyl (p)
Admission CRP	–	–	0.232* (0.038–0.409)	0.019
CRP at 24 h (mg/L)	0.574** (0.426–0.692)	< 0.001	0.325** (0.138–0.489)	0.001
ESR at admission (mm/h)	0.553** (0.401–0.675)	< 0.001	0.256** (0.064–0.430)	0.010
ESR at 24 h (mm/h)	0.539** (0.384–0.664)	< 0.001	0.160 (0.037–0.345)	0.109
APSP at 30 min (NRS 0–10)	0.062 (0.013–0.154)	0.536	0.150 (0.047–0.336)	0.133
APSP at 24 h (NRS 0–10)	0.246* (0.053–0.421)	0.043	0.279** (0.088–0.450)	0.005
Intraoperative fentanyl dose (mL; 50 µg/mL)	0.232* (0.038–0.409)	0.019	–	–

Pearson's correlation (two-tailed);
*p < 0.050;
**p < 0.010;
CRP – C-reactive protein; ESR – erythrocyte sedimentation rate; APSP – acute postoperative pain; NRS – numerical rating scale

fentanyl dose, age and BMI (p = 0.014). Intraoperative fentanyl dose was also independently associated with maximum 24-hour APSP (p = 0.007), whereas preoperative ESR, age, BMI and surgical group were not independently associated with this outcome.

Inflammatory marker levels in relation to surgical extent in breast tumor surgery

The mean CRP on admission for the whole cohort was 3.75 ± 0.55 mg/L (range 0.6–36.2). By group, mean admission CRP values were as follows: C, 1.96 ± 0.37 mg/L (0.6–8.5); M, 7.08 ± 1.86 mg/L (0.6–36.2); T, 3.46 ± 0.73 mg/L (0.6–14.5); and T + A, 2.5 ± 0.39 mg/L (0.6–7.3). Between-group comparisons showed that patients undergoing mastectomy (M) had significantly higher circulating CRP on admission than those who underwent tumor excision (T) (ANOVA, post hoc LSD, p < 0.05), tumor excision with axillary dissection (T + A) (ANOVA, post hoc LSD, p < 0.01), and excision of a benign lesion (C) (ANOVA, post hoc LSD, p < 0.01) (Figure 2A).

The mean CRP at 24 hours postoperatively for the whole cohort was 14.17 ± 1.41 mg/L (range 0.6–82.4). By group, mean postoperative CRP values were as follows: C, 5.22 ± 1.14 mg/L (0.6–23.4); M, 27.54 ± 3.61 mg/L (3.9–82.4); T, 11.96 ± 1.8 mg/L (0.9–34.9); and T + A, 13.11 ± 2.19 mg/L (0.9–43.6). Comparisons across groups, stratified by surgical extent, showed that patients who underwent mastectomy (M) had significantly higher circulating CRP at 24 hours than those who underwent tumor excision (T) (ANOVA, post hoc Games–Howell, p < 0.05), tumor excision with axillary dissection (T + A) (ANOVA, post hoc Games–Howell, p < 0.05), and excision of a benign lesion (C) (ANOVA, post hoc Games–Howell, p < 0.001) (Figure 2B).

The mean ESR on admission was 23.62 ± 1.75 mm/h (range 2–75). By group, mean admission ESR values were as follows: C, 14.32 ± 2.32 mm/h (2–49); M, 33.48 ± 3.86 mm/h (9–75); T, 24.71 ± 3.06 mm/h (2–60); and T + A, 22.8 ± 3.98 mm/h (2–73). Between-group comparisons showed significantly higher ESR on admission in patients who underwent mastectomy (M) compared with those who had excision of a benign lesion (C) (ANOVA: F = 6.050; post hoc Bonferroni, p < 0.001) (Figure 3A).




Figure 2. C-reactive protein (CRP) by surgical group; (A) admission CRP (mg/L); one-way ANOVA with LSD post hoc: p < 0.05 (M *vs.* T); p < 0.01 (M *vs.* C; M *vs.* T + A); (B) CRP at 24 h (mg/L); one-way ANOVA with Games–Howell post hoc: p < 0.05 (M *vs.* T; M *vs.* T + A); p < 0.001 (M *vs.* C); data are mean ± SEM;
C – benign lesion excision; T – malignant tumorectomy; T + A – malignant tumorectomy with axillary dissection; M – mastectomy; significance: p < 0.050 (*), p < 0.010 (**), p < 0.001 (***)

At 24 hours after surgery, the cohort's mean ESR was 20.09 ± 1.55 mm/h (range 2–64). Across groups, postoperative means were as follows: C, 11.46 ± 1.61 mm/h (2–31); M, 26.28 ± 3.48 mm/h (2–64); T, 24.71 ± 3.06 mm/h (2–60); and T + A, 18 ± 3.22 mm/h (2–55). Comparative




Figure 3. Erythrocyte sedimentation rate (ESR) by surgical group; (A) admission ESR (mm/h); one-way ANOVA with Bonferroni post hoc: $p < 0.001$ (M *vs*. C); (B) ESR at 24 h (mm/h); one-way ANOVA with Games–Howell post hoc: $p < 0.010$ (C *vs*. M; C *vs*. T); data are mean ± SEM;
C – benign lesion excision; T – malignant tumorectomy; T + A – malignant tumorectomy with axillary dissection; M – mastectomy; significance: $p < 0.010$ (**), $p < 0.001$ (***)

analysis by surgical extent indicated significantly lower postoperative ESR in the benign excision group (C) than in the mastectomy group (M) (ANOVA, post hoc Games–Howell, $p < 0.01$) and the tumor excision group (T) (ANOVA: $F = 5.863$; post hoc Games–Howell, $p < 0.01$) (Figure 3B).

Intraoperative fentanyl dose and acute postoperative pain

There was a statistically significant positive correlation between intraoperative fentanyl dose and the maximum intensity of acute postoperative pain at 24 h (Pearson's $r = 0.279$; 95% CI 0.088–0.450; $p < 0.01$; Table 1). For the cohort overall, the mean intraoperative fentanyl volume was 5.47 ± 0.19 mL (range 0.5–10). By group, the means were as follows: C, 4.17 ± 0.24 mL (2–8); M, 7.28 ± 0.3 mL (5–10); T, 4.52 ± 0.32 mL (0.5–7); and T + A, 6.35 ± 0.27 mL (4–8). Patients in the benign excision group (C) received significantly less fentanyl than those who underwent mastectomy (M) (ANOVA, post hoc Games–Howell, $p < 0.001$) and those who had tumor excision with




Figure 4. Intraoperative fentanyl by surgical group; mean intraoperative fentanyl volume (mL; 50 μg·mL^{-1} solution); one-way ANOVA with Games–Howell post hoc: $p < 0.001$ (C *vs*. M; C *vs*. T + A); data are mean ± SEM;
C – benign lesion excision; T – malignant tumorectomy; T + A – malignant tumorectomy with axillary dissection; M – mastectomy; significance: $p < 0.001$ (***)

axillary dissection (T + A) (ANOVA: $F = 26.544$; post hoc Games–Howell, $p < 0.001$) (Figure 4).

The mean maximum postoperative pain intensity within 30 minutes ($T_{0.5}$) of surgery for the cohort was 2.56 ± 0.21 (range 0–8). By group, the means were as follows: C, 2.11 ± 0.37 (0–8); M, 1.92 ± 0.32 (0–5); T, 3.35 ± 0.48; and T + A, 2.9 ± 0.46 (0–8). Between-group comparison showed a significant difference at 30 minutes, with patients who underwent excision of a malignant tumor (T) reporting higher maximum pain intensity than those with excision of a benign lesion (C) (ANOVA: $F = 2.786$; post hoc LSD, $p < 0.05$) (Figure 5A).

The mean maximum postoperative pain intensity within 24 hours (T_{24}) for the cohort was 2.17 ± 0.21 (range 0–8). By group, the means were: C, 1.5 ± 0.31 (0–5); M, 2.16 ± 0.39 (0–6); T, 2.35 ± 0.37 (0–5); and T + A, 2.85 ± 0.59 (0–8). There were no statistically significant differences between groups in maximum pain intensity within 24 hours of surgery (ANOVA: $F = 1.810$; $p = 0.150$) (Figure 5B).

DISCUSSION

We set out to examine whether routine inflammatory markers and intraoperative opioid exposure relate to early pain after breast tumor surgery across different procedures. In this single-centre prospective cohort, we observed three robust signals. First, higher preoperative CRP predicted more intense pain 24 h after breast tumor surgery, whereas ESR did not. Second, CRP and ESR rose in proportion to surgical magnitude. Thus, patients undergoing mastectomy exhibited the highest baseline and postoperative CRP and ESR values, followed by those receiving axillary dissection, tumorectomy, and benign excision. Third, the total intraoperative fentanyl dose correlated positively with both




Figure 5. Maximum postoperative pain by surgical group; (A) maximum pain intensity at 30 minutes [numerical rating scale (NRS), 0–10]; one-way ANOVA with LSD post hoc: $p < 0.050$ (C *vs.* T); (B) maximum pain intensity within 24 h (NRS, 0–10); no between-group differences (one-way ANOVA, $p = 0.150$); data are mean ± SEM;
C – benign lesion excision; T – malignant tumorectomy; T + A – malignant tumorectomy with axillary dissection; M – mastectomy;
significance: $p < 0.050$

inflammatory load and 24-hour pain intensity, suggesting a neuroimmune opioid–pain feedback loop. Although mean numerical rating scale scores at 24 hours were generally mild, up to 40% of individuals still reported clinically relevant pain (NRS ≥ 4), confirming that breast surgery, even in the era of enhanced recovery, remains a procedure with substantial nociceptive burden.

Our findings align with growing evidence that low-grade systemic inflammation primes postoperative pain. Associations between perioperative CRP dynamics and acute postoperative pain have been demonstrated in other surgical populations, including total knee arthroplasty [15]. Evidence specific to breast surgery remains limited, with signals reported in mastectomy cohorts and studies linking systemic inflammation to early postoperative recovery [9, 10]. CRP generally outperforms ESR as a short-term index of inflammatory flux, consistent with its biology, while ESR is slower and more influenced by chronic processes (e.g., anemia, age) [8]. Our mastectomy subgroup showed a four-fold higher mean CRP at 24 hours than the benign excision subgroup, reinforcing the concept that tissue load predicts systemic inflammation. The gradient we observed in inflammatory response across surgical extent mirrors prior evidence that postoperative CRP kinetics vary according to the type and magnitude of surgical trauma [16]. Despite such biological gradients, early pain scores did not differ between groups at 24 hours. Two non-mutually exclusive explanations are plausible. First, effective multimodal analgesia may have equalised pain perception; second, the NRS, while valid and practical, captures only intensity, not qualitative dimensions such as movement-evoked pain [17]. Future studies incorporating quantitative sensory testing and breast surgery-specific patient-reported outcome measures may reveal more nuanced group differences [18].

Mechanistic insights

The breast cancer microenvironment is characterized by tumor-associated macrophages, fibroblasts and cytokines that elevate circulating CRP and other acute-phase reactants [19]. High preoperative CRP in mastectomy patients therefore likely reflects both tumor-driven inflammation and subclinical systemic inflammation secondary to comorbidities (obesity, metabolic syndrome) [20]. Tissue trauma may amplify this inflammatory state through the release of damage-associated molecular patterns and activation of inflammatory signalling pathways, including nuclear factor κB, within the tumor and perioperative immune microenvironment [21].

Activated nociceptors express pattern-recognition receptors; IL-1β and tumor necrosis factor trigger ion-channel phosphorylation that lowers firing thresholds, while Fcγ-receptor signaling engaged by CRP–immune complexes at the neuroimmune interface can enhance excitability. Hence, patients entering theatre with high CRP may begin their postoperative course with a "primed" nociceptive system, explaining the correlation we observed.

Preclinical and translational data suggest that opioid exposure can interact with microglial and neuroinflammatory pathways, increasing proinflammatory signalling and potentially contributing to paradoxical postoperative pain amplification [22]. These mechanisms are concordant with experimental and translational evidence implicating neuroinflammatory and inflammasome pathways in opioid-induced hyperalgesia and tolerance [14]. In our cohort, higher fentanyl requirements paralleled CRP and ESR elevations and predicted greater 24-h pain, supporting this paradigm and suggesting that opioid sparing may attenuate neuroimmune sensitization.

Clinical implications

Routine perioperative CRP measurement could be an inexpensive tool for risk stratification. Patients whose CRP exceeds a yet-to-be-defined threshold might benefit from intensified, opioid-sparing multimodal analgesia, including regional techniques and non-opioid analgesic adjuncts where appropriate [23].

Persistent inflammation is strongly linked to chronic pain; after breast cancer treatment, clinically relevant

shoulder or chest-wall pain remains common months after surgery [24]. Identifying a high-inflammation phenotype preoperatively may offer an opportunity to intervene before the transition to chronic pain occurs. Longer-term follow-up of this cohort will determine whether baseline CRP adds prognostic value to existing chronic pain prediction models.

Our data also prompt re-evaluation of routine opioid dosing in breast surgery. Adoption of regional anesthesia (paravertebral or pectoral nerve blocks) and adjuvants that reduce systemic opioid exposure may diminish both inflammation and hyperalgesic potential, ultimately improving short- and long-term outcomes [12, 14, 23].

Limitations

Strengths of this study include a prospective design, simultaneous measurement of two biomarkers and inclusion of a benign-tumor control group, enabling separation of tumor-driven from surgery-driven inflammation. Limitations comprise single-center scope, modest sample size per stratum and reliance on a unidimensional pain scale. The exclusion of regional blocks, while methodologically necessary to isolate the inflammation–pain axis, limits generalizability to settings where such analgesia is standard. Finally, we did not measure pro- and anti-inflammatory cytokines or genetic polymorphisms that might refine mechanistic understanding.

CONCLUSION

Proinflammatory status, captured by CRP but not ESR, is an independent determinant of early pain after breast tumor surgery. Surgical magnitude and intraoperative opioid dose further modulate the inflammatory–pain axis. Routine CRP assessment may guide personalized analgesic strategies and offers a biomarker target for trials aimed at preventing persistent postsurgical pain.

Future studies should establish and externally validate simple, bedside CRP thresholds that predict clinically meaningful 24–48 h pain, and test whether dampening perioperative inflammation, via optimized multimodal care and selective anti-inflammatory strategies (e.g., perioperative corticosteroids or IL-6 pathway modulation), reduces acute pain and subsequent persistence. Prediction models ought to incorporate psychophysical and psychosocial measures alongside biology to reflect the broader pain network. Finally, randomized trials comparing opioid-sparing *vs.* opioid-rich anesthesia, with immune profiling and rigorous pain phenotyping, are needed to clarify the opioid–cytokine interface and its impact on short- and longer-term outcomes.

Ethics: This study was approved by the Institutional Ethics Committee of the Bežanijska Kosa Clinical Hospital Centre (protocol No. 4831/1, 22.07.2022). All participants provided written informed consent prior to enrolment. Consent for publication of anonymized study data was obtained.

Conflict of interest: None declared.

REFERENCES

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. [DOI: 10.3322/caac.21834] [PMID: 38572751]
2. Cheifetz R, McKevitt E. Advances in the surgical treatment of breast cancer. Curr Oncol. 2023;30(11):9584–6. [DOI: 10.3390/curroncol30110693] [PMID: 37999113]
3. Paladini A, Rawal N, Coca Martinez M, Trifa M, Montero A, Pergolizzi J Jr, et al. Advances in the management of acute postsurgical pain: a review. Cureus. 2023;15(8):e42974. [DOI: 10.7759/cureus.42974] [PMID: 37671225]
4. Chiang DLC, Rice DA, Helsby NA, Somogyi AA, Kluger MT. The incidence, impact, and risk factors for moderate to severe persistent pain after breast cancer surgery: a prospective cohort study. Pain Med. 2023;24(9):1023–34. [DOI: 10.1093/pm/pnad065] [PMID: 37184910]
5. Echeverria-Villalobos M, Tortorici V, Brito BE, Ryskamp D, Uribe A, Weaver T. The role of neuroinflammation in the transition of acute to chronic pain and the opioid-induced hyperalgesia and tolerance. Front Pharmacol. 2023;14:1297931. [DOI: 10.3389/fphar.2023.1297931] [PMID: 38161698]
6. Farrell SF, Armfield NR, Cabot PJ, Elphinston RA, Gray P, Minhas G, et al. C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factors. J Pain. 2024;25(2):476–96. [DOI: 10.1016/j.jpain.2023.09.008] [PMID: 37741522]
7. Altun Güvenir A, Çalışkan Uçkun A, Yurdakul FG, Bodur H. What does pain sensitivity really predict in rheumatoid arthritis patients? Agri. 2025;37(1):50–8. [DOI: 10.14744/agri.2024.30643] [PMID: 39835952]
8. Litao MKS, Kamat D. Erythrocyte sedimentation rate and C-reactive protein: how best to use them in clinical practice. Pediatr Ann. 2014;43(10):417–20. [DOI: 10.3928/00904481-20140924-10] [PMID: 25290132]
9. Hashimoto K, Tsuji A, Takenaka S, Ohmura A, Ueki R, Noma H, et al. C-reactive protein level on postoperative day one is associated with chronic postsurgical pain after mastectomy. Anesth Pain Med. 2018;8(4):e79331. [DOI: 10.5812/aapm.79331] [PMID: 30250822]
10. Radin AS, Bower JE, Irwin MR, Asher A, Hurvitz SA, Cole SW, et al. Acute health-related quality of life outcomes and systemic inflammatory markers following contemporary breast cancer surgery. NPJ Breast Cancer. 2022;8(1):91. [DOI: 10.1038/s41523-022-00456-4] [PMID: 35941136]
11. Golara A, Kozłowski M, Lubikowski J, Cymbaluk-Płoska A. Types of breast cancer surgery and breast reconstruction. Cancers (Basel). 2024;16(18):3212. [DOI: 10.3390/cancers16183212] [PMID: 39335183]
12. Clephas PRD, Orbach-Zinger S, Gosteli-Peter MA, Hoshen M, Halpern S, Hilber ND, et al. Regional analgesia techniques for postoperative pain after breast cancer surgery: a network meta-analysis. Cochrane Database Syst Rev. 2025;6(6):CD014818. [DOI: 10.1002/14651858.CD014818.pub2] [PMID: 40464297]
13. Holm JB, Baggesen E, Cronin-Fenton D, Frystyk J, Bruun JM, Christiansen P, et al. Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups. Sci Rep. 2024;14(1):14486. [DOI: 10.1038/s41598-024-64428-3] [PMID: 38914635]
14. Zare N, Sharafeddin F, Montazerolghaem A, Moradiannezhad N, Araghizadeh M. NLRs and inflammasome signaling in opioid-induced hyperalgesia and tolerance. Inflammopharmacology. 2024;32(1):127–48. [DOI: 10.1007/s10787-023-01402-x] [PMID: 38153538]
15. Springborg AH, Kehlet H, Nielsen NI, Gromov K, Troelsen A, Varnum C, et al. Perioperative association between c-reactive protein, pain catastrophizing and acute pain after total knee arthroplasty: a secondary analysis of two randomised trials. Acta Anaesthesiol Scand. 2024;68(9):1215–22. [DOI: 10.1111/aas.14476] [PMID: 39268561]

16. Sereda AP, Rukina AN, Trusova YV, Dzhavadov AA, Cherny AA, Bozhkova SA, et al. Dynamics of C-reactive protein level after orthopedic surgeries. J Orthop. 2024;47:1–7. [DOI: 10.1016/j.jor.2023.11.014] [PMID: 38046451]
17. Gilron I, Lao N, Carley M, Camiré D, Kehlet H, Brennan TJ, et al. Movement-evoked pain versus pain at rest in postsurgical clinical trials and in meta-analyses: an updated systematic review. Anesthesiology. 2024;140(3):442–9. [DOI: 10.1097/ALN.0000000000004850] [PMID: 38011045]
18. Malapati SH, Hyland CJ, Liang G, Edelen MO, Fazzalari A, Kaur MN, et al. Use of patient-reported outcome measures after breast reconstruction in low- and middle-income countries: a scoping review. J Patient Rep Outcomes. 2024;8(1):25. [DOI: 10.1186/s41687-024-00687-y] [PMID: 38416222]
19. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. [DOI: 10.1158/2159-8290.CD-21-1059] [PMID: 35022204]
20. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31–55. [DOI: 10.1016/j.immuni.2021.12.013] [PMID: 35021057]
21. Cao Y, Yi Y, Han C, Shi B. NF-κB signaling pathway in tumor microenvironment. Front Immunol. 2024;15:1476030. [DOI: 10.3389/fimmu.2024.1476030] [PMID: 39493763]
22. Xu Y, Chen R, Zhi F, Sheng S, Khiati L, Yang Y, et al. δ-opioid receptor, microglia and neuroinflammation. Aging Dis. 2023;14(3):778–93. [DOI: 10.14336/AD.2022.0912] [PMID: 37191426]
23. Kianian S, Bansal J, Lee C, Zhang K, Bergese SD. Perioperative multimodal analgesia: a review of efficacy and safety of the treatment options. Anesthesiol Perioper Sci. 2024;2(1):9. [DOI: 10.1007/s44254-023-00043-1]
24. Strijbos BTM, Janssen L, Voogd AC, Zwaans WAR, Roumen RMH, Maaskant-Braat AJG. Persistent pain after breast cancer treatment, an underreported burden for breast cancer survivors. Ann Surg Oncol. 2024;31(10):6753–63. [DOI: 10.1245/s10434-024-15682-2] [PMID: 38940899]

Преоперативни *C*-реактивни протеин предвиђа бол првог постоперативног дана након операције тумора дојке

Бојана Видовић[1], Ана Секулић[1,2], Сања Вигњевић Петриновић[3], Наташа Чолаковић[1,2], Симона Петричевић[1,2], Милан Гојгић[1], Барбара Лобода[1], Дарко Здравковић[1,2]

[1]Универзитетски клиничко-болнички центар „Бежанијска коса", Београд, Србија;
[2]Универзитет у Београду, Медицински факултет, Београд, Србија;
[3]Универзитет у Београду, Институт од националног значаја за Републику Србију, Институт за медицинска истраживања, Београд, Србија

САЖЕТАК

Увод/Циљ Субклиничка инфламација је важан фактор у настанку постоперативног бола, али њена улога у хирургији тумора дојке није потпуно разјашњена.

Циљ рада био је да се испитају вредности преоперативног *C*-реактивног протеина (*CRP*) или седиментације еритроцита (*SE*) у предикцији акутног постоперативног бола (*APSP*), утицај обима хируршке интервенције на периоперативни инфламаторни одговор, као и повезаност интраоперативне примене фентанила са интензитетом бола.

Методе Проспективна, једноцентрична кохортна студија обухватила је 101 одраслог болесника код којег је планирана операција дојке. Болесници су били подељени у четири групе: мастектомија (*M*, *n* = 25), туморектомија (*T*, *n* = 28), туморектомија са аксиларном дисекцијом (*T* + *A*, *n* = 20) и ексцизија бенигних промена (*C*, *n* = 28). Венска крв је узимана при пријему (*T*0) и након 24 сата (*T*24). Бол је процењиван помоћу нумеричке скале (0–10) 30 минута након буђења из анестезије и након 24 сата; највиша вредност бола у прва 24 сата (*max-APSP*) била је примарни исход.

Резултати Преоперативни *CRP* био је у корелацији са *max-APSP* ($p = 0,043$), док *SE* није показала значајну повезаност ($p = 0,11$). Почетне вредности *CRP*-а и *SE*, као и њихов пораст након 24 сата, расли су пропорционално обиму хируршке интервенције, а највише вредности забележене су код мастектомије (почетни *CRP* 7,1 ± 1,9 *mg/L*; *T24* 27,5 ± 3,6 *mg/L*; оба $p < 0,01$ у односу на остале групе). Интраоперативна примена фентанила била је у корелацији са *CRP*-ом након 24 сата ($r = 0,33$, $p = 0,001$) и са *max-APSP* ($r = 0,28$, $p = 0,005$).

Закључак Преоперативна системска инфламација представља независан предиктор раног постоперативног бола након хирургије тумора дојке. Обим интервенције појачава инфламаторни одговор, док већа примена фентанила прати већи степен инфламације и интензитет бола. Рутинско одређивање *CRP*-а у периоперативном периоду може помоћи у идентификацији болесника са високим ризиком и омогућити примену циљаних антиинфламаторних аналгетских стратегија и стратегија којима се смањује употреба опиоида, ради смањења акутног бола и потенцијалне превенције хроничног бола.

Кључне речи: акутни постоперативни бол; хирургија тумора дојке; *C*-реактивни протеин; седиментација еритроцита